Farooq Sheikh

With the changing landscape in #CAV management, this State of the Art Review on CAV explores how precision medicine may affect and change how we assess and manage CAV. @jukakimMD @NatalieTapaskar @KiranKhush1 @JoyceNjorogeMD 🔗: jhltonline.org/article/S1053-…

Great kickoff at #CRTheartfailure by Mandeep R. Mehra. Mortality & morbidity (M&M) in heart failure remain unacceptably high—even in the era of contemporary GDMT. Clear reminder that despite progress, there is still much work to do. @fsheikh22 @MarkHofmeyer @RichaGuptaMD @samernajj

A lot of us have noticed that our ATTR-CM patients have commonly led extremely active lives. From a Danish matched cohort - occupations in agricultural work and higher upper-body load suggest mechanical stress as a risk signal. doi.org/10.1016/j.jaca…

2-year outcomes from the DOAC-LVAD study-showing feasibility of using apixaban in CF-LVAD patients. Presented at #GRS2025 and now out in #JHLT #LVAD #cardiotwitter @AdityaMehtaMD @PalakShahMD @coconnormd 🫀 🔗: jhltonline.org/article/S1053-…

@Ron_Witteles @dr_pavia @maz_hanna @MathewMaurer Congratulations!

Proud of this work with wonderful colleagues - 2025 Position Statement on Monitoring ATTR-CM, with a focus on defining “progression” - check it out! sciencedirect.com/science/articl…

Shoutout to our national and international attendees! 📢 Thank you for attending from all around the globe, virtual and in person! 🌍 🖥️ #ChiHemos25 #Cardiology #Fellows #HeartFailure #Hemodynamics #CardioTwitter

@rblument1 @WendyPost9 Happy birthday!!

Happy “39th” 🎂 to my favorite clinician-scientist & translational researcher who is a wonderful wife, mom, & friend ⁦@WendyPost9⁩

5/ Other findings: 🛑Disparities in #LVAD utilization disfavoring women and Black pts are amplified in older adults. This, despite older 👵having better 5-yr survival than👴. Pre-proof available @annalsthorsurg here: annalsthoracicsurgery.org/article/S0003-… @TomHanffMD @noshreza @JasonKatzMD

Selective in vitro enhancement of cardiac myosin motor function and myofilament force generation by danicamtiv prompted clinical evaluation. A short course of danicamtiv was generally well tolerated in participants with #DCM. jacc.org/doi/10.1016/j.… #HFSA2025 #JACC #cvGenetics

🚨 Just released in @JCardFail - the @HFSA HF Stats 2025 report! 💔1 in 4 Americans will develop heart failure in their lifetime 💲Costs could soar to $858B by 2050 📖 Read the report ➡️ onlinejcf.com/article/S1071-… 📺 Watch the highlights w/ @gcfmd ➡️ youtu.be/0fq_wF4IxoU #HFStats2025 #heartfailurestats

@JohanaFajardDNP @AAHFN @HFSA @PhilLamMD @RichaGuptaMD @MarkHofmeyer @MedStarHealth @cjbither

@JohanaFajardDNP @AAHFN @HFSA @PhilLamMD @RichaGuptaMD @MarkHofmeyer @MedStarHealth

Hiring Alert! MedStar Health is seeking a Nurse Practitioner (NP) or Physician Assistant (PA) to join our Infiltrative Cardiomyopathy Program within the Advanced Heart Failure team at MedStar Washington Hospital Center. See job posting below:

Presented at #ESCCongress: In patients with heart failure and reduced ejection fraction who were receiving guideline-directed medical therapy, digitoxin lowered the risk of death or hospitalization for heart failure as compared with placebo. Full DIGIT-HF phase 4 trial results: nej.md/3HQHLfj @escardio

Consensus statement by Kobashigawa & Zuckermann et al. reviews evaluation/management of circulating #antibodies before & after #HeartTx, and antibody-mediated rejection. @SmidtHeart @ManlaYosef 🔗: jhltonline.org/article/S1053-…

Single-nucleus RNA-seq reveals CD47 as a key driver of doxorubicin cardiomyopathy. Blocking CD47 protects the heart—offering a new therapeutic path. 🫀🧬@SDPrabhuMD @AartiAsnaniMD @BKopeckyMDPhD @twinsmc18 @AhmedAADiab @carmenbergom @Alicardsdoc ahajournals.org/doi/full/10.11…

🚨 Hot off the press: JACC Advances SGLT2i ↓ myocardial glucose uptake on FDG-PET: ▪️ 374-pt matched cohort ▪️ “No uptake” in 65 % on SGLT2i vs 37 % controls ▪️ Total myocardial glycolysis ⬇️ despite ↑ prescan glucose Metabolic shift may underlie CV benefits & carries implications for PET imaging protocols involving patients on SGLT2i. Led by @BrettSperryMD @MidAmericaHeart doi.org/10.1016/j.jaca…

@CiccaroneCenter @hopkinsheart @rblument1 Congratulations @rblument1

Congratulations to our very own @rblument1 on a well deserved award! 🫀 We are proud to have the father of modern preventive cardiology as our director.

“Out of Sequence Heart Transplants: Why, How Many, and to Whom” Our new analysis in ⁦@TheJHLT⁩ on the prevalence and factors associated with out of sequence heart allocation ⁦@ColumbiaCVRI⁩ ⁦ jhltonline.org/article/S1053-…